Sarah Cannon Research Institute (SCRI) principal investigators authored fourteen abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting 2013, which runs from April 6-10 in Washington, D.C.
“SCRI’s growing presence at the AACR annual meeting reinforces the ability of our scientific leadership to develop and deliver more effective investigational agents,” said Howard A. Burris III, M.D., SCRI’s chief medical officer and executive director, drug development. “By introducing such innovative approaches, we are furthering our mission of advancing therapies for patients.”
